The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenases mRNA expressions in breast carcinomas

Histology and Histopathology

Volumn 19, Issue 1, 2004, Pages 129-136

  Li, H ^a,b   Suo, Zhenhe ^b   Zhang, Y ^a   Risberg, B ^b   Karlsson, M G ^c   Villman, K ^c   Nesland, J M ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF OSLO   (Norway)

^c ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Breast carcinoma; DPD; PCR; TP; TS

Indexed keywords

CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; SWEDEN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 1642474408     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Aishima Si. S., Taguchi K.K., Sugimachi, K., Asayama, Y., Nishi H., Shimada M. and Tsuneyoshi, M. (2002). The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma. Int. J. Surg. Pathol. 10, 47-56.
2. Anan K., Mitsuyama S., Tamae K., Suehara N., Nishihara K., Ogawa Y., Abe Y., Iwashita T. and Toyoshima S. (2003). Increased dihydropyrimidine dehydrogenase activity in breast cancer. J. Surg. Oncol. 82, 174-179.
3. Baisch H., Beck, H.P., Christensen I.J., Hartmann N.R., Fried J., Dean P.N., Gray J.W., Jet J.H., Johnston D.A., White R.A., Nicolini C., Zeitz S. and Watson J.V. (1982). A comparison of mathematical methods for the analysis of DNA histograms obtained by flow cytometry. Cell Tissue Kinet. 15, 235-249.
4. Bathe O.F., Francheschi D., Livingstone A.S., Moffat F.L., Tian E. and Ardalan B. (1999). Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival. Cancer J. Sci. Am. 5, 34-40.
5. Cascinu S., Aschele C., Barni S., Debernardis D., Baldo C., Tunesi G., Catalano V., Staccioli M.P., Brenna A., Muretto P. and Catalano G. (1999). Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin. Cancer Res. 5, 1996-1999.
6. Corsi D.C., Ciaparrone M., Zannoni G., Mancini M., Cassano A., Specchia M., Pozzo C., Martini M. and Barone C. (2002). Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur. J. Cancer, 38, 527-534.
7. Diasio R.B. (1999). Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt). 13, 17-21.
8. Diasio R.B. and Harris B.E. (1989). Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet 16, 215-237.
9. Edler D., Hallstrom M., Johnston P.G., Magnusson I., Ragnhammar P. and Blomgren H. (2000). Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6, 1378-1384.
10. Elston C.W. and Ellis I.O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19, 403-410.
11. Fox S.B., Westwood M., Moghaddam A., Comley M., Turley H., Whitehouse R.M., Bicknell R., Gatter K.C. and Harris A.L. (1996). The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br. J. Cancer 73, 275-280.
12. Hagiwara K., Stenman G., Honda H., Sahlin P., Andersson A., Miyazono K., Heldin C.H., Ishikawa F. and Takaku F. (1991). Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene. Mol. Cell Biol. 11, 2125-2132.
13. Hamaji M., Miyazaki S., Nishida Y., Izukura, M., Nishijima J., Oka Y., Seshimo I. and Ohwari M. (2000). A preliminary study on dihydropyrimidine dehydrogenase activity in breast cancer. Gan To Kagaku Ryoho 27, 1719-1724.
14. Horiguchi J., Takei H., Koibuchi Y., Iijima K., Ninomiya J., Uchida K., Ochiai R., Yoshida M., Yokoe T., Iino Y. and Morishita Y. (2002). Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br. J. Cancer, 86, 222-225.
15. Horikoshi T., Danenberg K.D., Stadlbauer T.H., Volkenandt M., Shea L.C., Aigner K., Gustavsson B., Leichman L., Frosing R. and Ray M. (1992). Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res. 52, 108-116.
16. Iltzsch M.H., El Kouni M.H. and Cha S. (1985). Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry 24, 6799-68807.
17. Johnston P.G., Fisher E.R., Rockette H.E., Fisher B., Wolmark, N., Drake J.C., Chabner B.A. and Allegra C.J. (1994). The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12, 2640-2647.
18. Kanzaki A., Takebayashi Y., Bando H., Eliason J.F., Watanabe S., Miyashita H., Fukumoto M., Toi M. and Uchida T. (2002). Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int. J. Cancer 97, 631-635.
19. Kawakami K., Salonga D., Park J.M., Danenberg K.D., Uetake H., Brabender J., Omura K., Watanabe G. and Danenberg P.V. (2001). Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7, 4096-4101.
20. Krenitsky T.A., Koszalka G.W. and Tuttle J.V. (1981). Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. Biochemistry 20, 3615-3621.
21. Lehman N.L. (2002). Future potential of thymidylate synthase inhibitors in cancer therapy. Exp. Opin. Investig. Drugs 11, 1775-1787.
22. Mizutani Y., Wada H., Ogawa O., Yoshida O., Fukushima M., Nonomura N. and Miki T. (2001). Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92, 510-518.
23. Mizutani Y., Wada H., Yoshida O., Fukushima M., Bonavida B., Kawauchi A. and Miki T. (2002). Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer. Oncol. Rep. 9, 289-292.
24. Nishimura G., Terada I., Kobayashi T., Ninomiya I., Kitagawa H., Fushida S., Fujimura T., Kayahara M., Shimizu K., Ohta T. and Miwa K. (2002). Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep. 9, 479-482
25. Nishimura R., Nagao K., Miyayama H., Matsuda M., Baba K., Matsuoka Y., Yamashita H., Fukuda M., Higuchi A., Satoh A., Mizumoto T. and Hamamoto R. (1999). Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 19, 5621-5626.
26. O'Brien T.S., Fox S.B., Dickinson A.J., Turley H., Westwood M., Moghaddam A., Gatter K.C., Bicknell R. and Harris A.L. (1996). Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56, 4799-4804.
27. Pestalozzi B.C., Peterson H.F., Gelber R.D., Goldhirsch A., Gusterson B.A., Trihia H., Lindtner J., Cortes-Funes H., Simmoncini E., Byrne M.J., Golouh R., Rudenstam C.M., Castiglione-Gertsch M., Allegra C.J. and Johnston P.G. (1997). Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol. 15, 1923-1931.
28. Rose M.G., Farrell M.P. and Schmitz J.C. (2002). Thymidylate synthase: A critical target for cancer chemotherapy. Clin. Colorectal Cancer 1, 220-229.
29. Salonga D., Danenber K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B. and Danenberg P.V. (2000). Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327.
30. Silverman G.A., Kuo W.L., Taillon-Miller P. and Gray J.W. (1993). Chromosomal reassignment: YACs containing both YES1 and thymidylate synthase map to the short arm of chromosome 18. Genomics 15, 442-445.
31. Suo Z., Berner H.S., Risberg B., Karlsson M.G. and Nesland J.M. (2001). Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch. 439, 62-69.
32. Takai S., Fernandez-salguero P., Kimura S., Gonzalez F.J. and Yamada K. (1994). Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization. Genomics 24, 613-614.
33. Takebayashi Y., Natsugoe S., Baba M., Akiba S., Fukumoto T., Miyadera K., Yamada Y., Takao S., Akiyama S. and Aikou T. (1999). Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 85, 282-289.
34. Takebayashi Y., Yamada K., Miyadera K., Sumizawa T., Furukawa T., Kinoshita F., Aoki D., Okumura H., Yamada Y., Akiyama S. and Aikou T. (1996). The activity and expression of thymidine phosphorylase in human solid tumours. Eur. J. Cancer 32A, 1227-1232.
35. Takenoue T., Kitayama J., Takei Y., Umetani N., Matsuda K., Nita M.E., Hatano K., Tsuruo T. and Nagawa H. (2000). Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann. Oncol. 11, 273-279.
36. Toi M., Hoshina S., Taniguchi T., Yamamoto Y., Ishitsuka H. and Tominaga T. (1995). Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int. J. Cancer 64, 79-82.
37. Van Triest B., Pinedo H.M., Blaauwgeers J.L., Van Diest P.J., Schoenmakers P.S., Voorn D.A., Smid K., Hoekman K., Hoitsma H.F. and Peters G.J. (2000). Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin. Cancer Res. 6, 1063-1072.
38. Vindelov L.L., Christensen I.J. and Nissen N.I. (1983). A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3, 323-327.
39. Yang Q., Sakurai T., Shan L., Yoshimura G., Yu Z., Suzuma T., Tamaki T., Umemura T., Nakamura Y., Nakamura M., Utsunomiya H., Mori I. and Kakudo K. (2000). Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer. Breast Cancer 7, 210-214.
40. Yang Q., Barbareschi M., Mori I., Mauri F., Muscara M., Nakamura M., Nakamura Y., Yoshimura G., Sakurai T., Caffo O., Galligioni E., Dalla Palma P. and Kakudo K. (2002a). Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int. J. Cancer 97, 512-517.
41. Yang Q., Yoshimura G., Mori I., Sakurai T. and Kakudo K. (2002b). Thymidine phosphorylase and breast carcinoma. Anticancer Res. 22, 2355-2360.